European regulators greenlight first clinical test of GLP-1 gene therapy

Drug developers are racing to develop gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now a company based just outside of Boston is poised to become the first to start a clinical trial of the potentially permanent approach. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell…

Source: Endpoints News